



3R MATRIX

	+	=	-
Right Sector (RS)	✓	✗	✗
Right Quality (RQ)	✓	✗	✗
Right Valuation (RV)	✓	✗	✗
+ Positive		= Neutral	- Negative

What has changed in 3R MATRIX

	Old		New
RS	✗	↔	✓
RQ	✗	↔	✓
RV	✗	↔	✓


Company details

Market cap:	Rs. 34,261 cr
52-week high/low:	Rs. 1,414 / 857
NSE volume: (No of shares)	14.97 lakh
BSE code:	524494
NSE code:	IPCALAB
Free float: (No of shares)	6.8 cr

Shareholding (%)

Promoters	46.3
FII	10.6
DII	34.1
Others	9.1

Price chart



Price performance

(%)	1m	3m	6m	12m
Absolute	10.5	6.3	16.0	53.4
Relative to Sensex	12.4	-2.1	4.7	32.5

Sharekhan Research, Bloomberg

Ipca Laboratories Ltd

Strong Q1; UniChem's turnaround sustainable

Pharmaceuticals

Sharekhan code: IPCALAB

Reco/View: Buy



Upgrade



CMP: Rs. 1,350

Price Target: Rs. 1,600



Downgrade

Summary

- Ipca's Q1FY2025 overall performance was above our estimates. Sales grew 32.9% y-o-y to Rs. 2,092 crore, EBITDA increased 28% y-o-y to Rs. 392 crore, and APAT rose 17% y-o-y to Rs. 192 crore.
- Segment-wise growth was seen across regions, where domestic branded formulation grew 12%, surpassing IPM growth of 8-9%. In the international segment, institution grew by 19%, offset by generic formulation declining 5%.
- A healthy product mix, raw-material cost rationalisation, and Unichem's profitability led to a 200bps y-o-y increase in gross margin to 69.2%; subsequently, EBITDA margin fell 60bps y-o-y to 18.8%. Management has increased its overall EBITDA margin guidance to 20.5-21% for FY2025E.
- Unichem business reported a healthy turnaround and resurgence of U.S. sales is expected to increase EBITDA margin to 21.5% by FY2026; hence, we maintain BUY. Currently, the stock is trading at ~35.6x/27.5x its FY2025E/FY2026E EPS and we ascribe a P/E of 32x to arrive at a PT of Rs. 1,600.

Ipca Laboratories Limited's (Ipca) earnings came above our estimates, as sales grew 32.9% y-o-y to Rs. 2,092 crore. Sales growth was led by 11.6% y-o-y growth in domestic branded formulations, surpassing Indian Pharmaceutical Market (IPM) growth of 8-9%, and 19% y-o-y growth in generic formulations, which offset the fall in the branded formulation segment to Rs. 112 crore. Subsidiary sales also grew by 432% y-o-y to Rs. 526 crore, led by growth in Unichem sales. Healthy sales and raw-material (RM) cost rationalisation, which contributed 30% to sales (vs. 33% of sales in Q1FY2025) resulted in a 200bps increase in gross margin. Subsequently, EBITDA grew 28% y-o-y to Rs. 392.7 crore. However, due to increased other expenses' contribution, EBITDA margin declined by 60bps to 19%. Healthy operations, a 23% y-o-y decline in finance cost to Rs. 24 crore, and 42% y-o-y growth in depreciation resulted into PAT growth of 20% y-o-y to Rs. 198 crore. This was the third quarter of full integration of Unichem's business. Going forward, management expects Unichem sales to grow to Rs. 9,000 crore and EBITDA of Rs. 1,600 crore. Hence, at a consolidated level, the company expects sales to grow to 10.5-11.5% in FY2025E and EBITDAM of 18% in FY2025E, which can further inch up to 24% in 5-6 years. The company launched two products in the U.S. market in Q1FY2025 and expects to launch 4-5 products in the remaining FY2025E and another 5-6 products in FY2026E, which would add to profitability. Ipca's subsidiary, Unichem is growing well and its EBITDA has improved from a loss of Rs. 45 crore in FY2023 to Rs. 100 crore in FY2024 and is expected to improve to Rs. 225 crore by FY2025E, which will in-turn increase its consolidated performance. Hence, we maintain our BUY recommendation on the stock.

Key positives

- Sales/EBITDA/PAT came in above our estimates by 4%, 3% and 15%, respectively
- The domestic formulations segment grew by 11.6% to Rs. 873 crore, surpassing IPM growth by 8-9%.
- Institutional business grew 19% y-o-y to Rs. 57.6 crore owing to a lower base.

Key negatives

- Generic formulations declined by 5% to Rs. 225 crore.

Management Commentary

- Management launched two products in Q1FY2025 and expects to launch another 5-6 products in FY2026 in the U.S. market.
- Unichem's EBITDA was -Rs. 45 crore last year, which saw a turnaround to Rs. 100 crore in CY2024 and is expected to reach Rs. 225 crore.
- Management expects the product mix to remain healthy, which drives EBITDA margin to 20-20.5% in FY2025E and towards 24% by 5-6 years.

Revision in estimates – Management has retained its guidance of improvement in Unichem's business, domestic growth outperforming IPM, and contribution of U.S. sales from FY2025E, which we have factored in our estimates. Hence, we have not revised our estimates.

Our Call

Valuation – Maintain BUY with a revised PT of Rs. 1,600: Ipca reported higher-than-expected earnings. Sales growth can be attributed to the integration of Unichem's business, followed by strong growth in the domestic branded generics and generics segments. A healthy product mix and RM cost rationalisation led to increased gross margin to 69% and EBITDA margin to 19%. Going forward, the company expects growth to be driven by 1) stable realisation in API prices, 2) domestic formulation growth, led by the chronic segment, 3) pick-up in the institution business, and 4) new product launches to spur U.S. growth. Additionally, the recent acquisition of Unichem Labs is expected to grow, driven by penetration into newer geographies such as Europe, Australia, New Zealand, Canada, and South Africa, resulting in an increase in EBITDA from Rs. 100 crore in FY2024 to Rs. 225 crore in FY2025E. Higher profitability in Unichem's business is expected to increase consolidated EBITDA margin to 20.5-21% in FY2025E and eventually grow to 24% in 5-6 years. On account of the turnaround in Unichem's business, we maintain our rating to BUY. Currently, the stock is trading at ~35.6x/27.5x its FY2025E/FY2026E EPS of Rs. 38.2/Rs. 27.5 per share. Due to the resurgence in U.S. sales and a positive turnaround of Unichem's business, we ascribe a P/E of 32x to arrive at a PT of Rs. 1,600 (earlier PT of Rs. 1,357).

Key Risks

- Delay in regulatory clearance of Pithampur and the Pipariya plants and 2) adverse changes in the regulatory landscape could affect its profitability.

Valuation (Consolidated)

Particulars	FY22	FY23	FY24	FY25E	FY26E
Sales	5766.8	6206.9	7660.4	9323.1	10721.6
EBITDA	1309.6	964.2	1321.2	1731.4	2143.0
EBITDA M (%)	22.7	15.5	17.2	18.6	20.0
PAT	884.4	471.3	622.8	969.5	1254.0
NPM (%)	15.3	7.6	8.1	10.4	11.7
EPS	34.8	18.6	24.5	38.2	49.4
P/E	39.0	73.1	55.3	35.6	27.5
P/BV	5.8	5.4	5.0	5.4	4.5
EV/EBITDA	23.8	32.2	33.5	25.0	17.2
ROE (%)	17.4	9.4	8.1	13.4	14.9
ROCE (%)	19.6	11.6	8.5	10.2	12.9

Source: Company Data; Sharekhan estimates

Q1FY2025 Concall highlights

Guidance –

- ◆ Consolidated revenue including Unichem is likely to be around Rs. 9,000 crore in FY2025E.
- ◆ Consolidated EBITDA stood at 18% in FY2025, excluding other income and foreign exchange gain.
- ◆ Domestic and export generic business is expected to grow by 12% in FY2025E.
- ◆ Institutional business is likely to grow by 14% in FY2025E.
- ◆ API business is expected to grow by 7% to 8% in FY2025E.
- ◆ Standalone revenue is likely to grow by 10.5% to 11% in FY2025E.
- ◆ Standalone EBITDA margin stands at 20.5-21% in FY2025E.
- ◆ Unichem business sales are expected to reach Rs. 20 billion and EBITDA is expected to reach around Rs. 2.25 billion in FY2025.
- ◆ Capex guided for FY2025E is around Rs.3-3.5 billion.
- ◆ Consolidated R&D spend for FY2025E will be at 3.25-3.5%.

India

- ◆ Domestic formulation business grew by 12% for Q1FY2025 and Ipca continued to be ranked at the 16th position in the IPM.
- ◆ IPCA has outperformed IPM, with 15% growth vs. 6% IPM growth.
- ◆ Market share improved to 2.04% from 1.88% as per IQVIA MAT June 2024.
- ◆ It reported 16% vs. 8% market growth in the top six metro cities.
- ◆ Ipca's domestic business was driven by growth in acute and chronic therapies.
- ◆ In the chronic segment, Ipca grew 12% vs. IPM growth of 10%.
- ◆ In the acute segment, Ipca grew 11% vs. IPM growth of 3%.
- ◆ Ipca emerged as the fastest-growing company in the top-25 players in IPM as per the IQVIA MAT March 2024.
- ◆ The company is currently focused on metro cities; and for these cities, the company has already added enough field force.
- ◆ In FY2025, the price increase for NLEM products is expected to be nil, price growth for non-NLEM products is expected to be 4-6% with volume growth of 5-6% and 2% growth expected from new products.

Exports

- ◆ Due to the issues at Silvassa and Pithampur plant, the company is seeing an excess expense of Rs. 500-600 million. Supplies to the U.S. have already begun from Silvassa, with the first batch already shipped.
- ◆ Pithampur plant utilisation stands at 35%.
- ◆ The company has not yet started ANDA filings from its facility, and management believes filing will take some more time as it looks forward to building a pipeline for the U.S. As the company was not present in the U.S. market for quite some time, all ANDAs need to be updated before supplying to the U.S. Currently, two products are in the pipeline and a few more are expected in FY2025.

Subsidiaries

- ◆ Onyx pharmaceuticals, U.K. develops new manufacturing processes for solid-state chemistry in the U.K., with a turnover of around GBP15-16million, and the company is consistently profitable.
- ◆ Tropic Wellness, which caters to Nutraceuticals for the company, has also generated good profits in FY2024 and remains profitable.
- ◆ Bayshore, now integrating with Unichem, was initially formed solely to market Ipca's products in the U.S. With the huge capacity of Unichem, the entire operations of Ipca will be done through Unichem, including the distribution of Ipca's products in the U.S.
- ◆ Pisgah, a subsidy created for the CRAMS business in the U.S., was established as an extension of the successful U.K.-based Onyx operations. Services are currently primarily provided by Onyx to European companies. Certain narcotics products and low-volume, high-value API production are present at Onyx, which also has two to three new commercial APIs in the pipeline and is under development for new drugs.

- ◆ PISGAH may host the production of newly launched commercial APIs once the volume increases, with some narcotics products currently in development at the facility. Although PISGAH is currently experiencing some small losses, these are expected to diminish as the CRAMS business expands.
- ◆ In the steroid business, profit is being delivered by Avik, one of the associate companies.
- ◆ Krebs, the fermentation operation company, is the only entity still struggling to achieve profitability. Despite introducing new products like Simvastatin and Shirasho peptides, utilising their large capacities, particularly the fermentation side, remains an ongoing effort with plans to explore contract manufacturing opportunities.

Unichem's consolidation

- ◆ Unichem's EBITDA improved from a loss of Rs. 45 crore in FY2023 to Rs. 100 crore in FY2024.
- ◆ Unichem and Ipca operate as separate entities, with integration benefits primarily seen in procurement, favouring Ipca by providing buying efficiency due to higher volume. Avoidance of duplication has led to reduced unnecessary costs, along with enhancements in expertise, utility cost reduction, and operational efficiency. Ipca is also sharing expertise with Unichem to lower API costs. Ongoing efforts are aimed at further cost reduction and generating synergies, such as low-cost APIs for Ipca.
- ◆ The significant advantage will be realised when Unichem's products are supplied to Europe, Australia, New Zealand, and South Africa, leading to larger integration benefits. Earlier, Unichem was only selling seven to nine products out of 80 in the region.
- ◆ A gradual ramp-up is expected in the U.S., with benefits derived from the export outlook due to Unichem's presence.
- ◆ Gross margin and pricing remain stable, with plans to launch 5-6 formulation products in the U.S. market.
- ◆ Procurement prices remain unchanged with steady pricing across the board.
- ◆ A major impact on APIs is observed with Losartan, where cost prices and manufacturing costs have stabilised.
- ◆ Only one plant underwent inspection, which was concluded without any observations.

Results (Consolidated)

Particulars	Rs cr				
	Q1FY2025	Q1FY2024	YoY %	Q4FY2024	QoQ %
Net Revenue	2,092.6	1,574.5	32.9	2,020.2	3.6
Raw materials costs	643.5	515.3	24.9	685.9	-6.2
Gross Profit	1,449.1	1,059.2	36.8	1,334.3	8.6
Operating Expenses	1,056.4	764.6	38.2	1,025.2	3.0
EBIDTA	392.7	307.6	27.7	321.9	22.0
Depreciation	98.9	69.3	42.8	98.1	0.8
EBIT	293.8	238.4	23.3	223.8	31.3
Interest	24.1	31.4	-23.4	29.4	-18.1
Other income	20.6	44.9	-54.0	18.9	8.9
PBT	290.4	251.8	15.3	213.3	36.1
Exceptional item	0	0	0.0	1367.2	-100.0
Tax	91	86	6.8	72	27.3
Reported PAT	199.0	166.2	19.7	2.9	6737.8
Minority Interest	69.0	12.8	NA	-566.8	NA
PAT after MI	192.1	164.9	16.5	59.6	NA
Adjusted EPS (Rs)	7.6	6.5	16.5	5.9	28.8
Margins			bps		bps
GPM (%)	69.2	67.3	198	66.0	320
EBITDA (%)	18.77	19.54	-77	15.93	283
Reported profit margin (%)	9.5	10.6	-105	0.1	936
Tax Rates (%)	31.5	34.0	-252	33.7	-219

Source: Company; Sharekhan Research

Outlook and Valuation

■ Sector Outlook – Multiple growth engines ahead

The IPM is growing with increased consumer spends and awareness. Additionally, Indian pharmaceutical companies with a large market share in the IPM and a strong pipeline of specialty products will help them gain market share in the U.S. and, thereby, partially offset any impact of competitive pricing pressure in the U.S. Moreover, other factors such as faster product approvals and resolutions by the USFDA regarding plant observations and strong growth prospects in domestic markets and emerging opportunities in the API space would be key growth drivers. This would be complemented by strong capabilities developed by Indian companies (leading to a shift towards complex molecules, biosimilars, and injectables) and the commissioning of expanded capacities by select players over the medium term. Collectively, this indicates a strong growth potential for Indian pharma companies going ahead.

■ Company Outlook – Long-term growth levers intact

Ipca is a fully integrated Indian pharmaceutical company, manufacturing a wide array of formulations and APIs for various therapeutic segments. The domestic formulations business is expected to grow at a healthy pace and is likely to be a key growth driver for the company. The company is witnessing strong demand traction in the API segment and is implementing de-bottlenecking to ease capacity constraints. Over the next year, Dewas's expansion would come on stream and drive the topline. Moreover, the company has set up a new API plant at its Ratlam facility with a 50MT capacity, which is on the verge of commercialisation. The expected improvement in the formulation business, increased opportunities in the API space, and healthy traction from the institutional segment indicate strong earnings potential for the company. In the near term, emerging cost pressures due to higher RM and logistics costs and time lag to pass on the price hike to customers coupled with de-stocking in key markets of Europe are expected to drag down growth. Consequently, while near-term growth seems to moderate, long-term growth levers are intact.

■ Valuation – Maintain BUY with a revised PT of Rs. 1,600

Ipca reported higher-than-expected earnings. Sales growth can be attributed to the integration of Unichem's business, followed by strong growth in the domestic branded generics and generics segments. A healthy product mix and RM cost rationalisation led to increased gross margin to 69% and EBITDA margin to 19%. Going forward, the company expects growth to be driven by 1) stable realisation in API prices, 2) domestic formulation growth, led by the chronic segment, 3) pick-up in the institution business, and 4) new product launches to spur U.S. growth. Additionally, the recent acquisition of Unichem Labs is expected to grow, driven by penetration into newer geographies such as Europe, Australia, New Zealand, Canada, and South Africa, resulting in an increase in EBITDA from Rs. 100 crore in FY2024 to Rs. 225 crore in FY2025E. Higher profitability in Unichem's business is expected to increase consolidated EBITDA margin to 20.5-21% in FY2025E and eventually grow to 24% in 5-6 years. On account of the turnaround in Unichem's business, we maintain our rating to BUY. Currently, the stock is trading at ~35.6x/27.5x its FY2025E/FY2026E EPS of Rs. 38.2/Rs. 27.5 per share. Due to the resurgence in U.S. sales and a positive turnaround of Unichem's business, we ascribe a P/E of 32x to arrive at a PT to Rs. 1,600.

About the company

Ipca is a fully integrated Indian pharmaceutical company manufacturing more than 350 formulations and 80 APIs for various therapeutic segments. Ipca is a therapy leader in India for anti-malaria with a market share of over 34% and a fast-growing presence in the international market as well. The company has leading brands in five therapeutic areas, with three of its branded formulations being ranked among the top-300 Indian brands by ORG-IMS. Ipca's APIs and formulations are produced at manufacturing facilities approved by leading drug regulatory authorities, including USFDA, UK-Medicines, Healthcare Regulatory Agency (MHRA), South Africa-Medicines Control Council (MCC), Brazil-Brazilian National Health Vigilance Agency (ANVISA), and Australia-Therapeutic Goods Administration (TGA) with operations in more than 100 countries.

Investment theme

Strong growth in the domestic formulation business coupled with increased opportunities in the API space and additional business from the institutional segment indicate strong earnings potential over the next 2-3 years. We feel most headwinds that impacted the company's sales and profitability (except for the import alert from USFDA) are now behind it. Management is also evaluating new therapeutic areas that would boost the company's overall growth. In addition, Ipca is implementing de-bottlenecking plans for its API facilities to ease capacity constraints. Further, Ipca is setting up new API capacities at Dewas and is looking to build the Nobel Expochem plant into a KSM plant. Collectively, incremental capacities are coming on stream and would fuel growth, though over the long term.

Key Risks

1) Lack/delay of clearance by other drug regulators would impact the export business outlook; 2) Addition of drugs in the NLEM list could hurt the domestic business.

Additional Data

Key management personnel

Premchand Godha	Chairman and Managing Director
Ajit Kumar Jain	Joint Managing Director
Harish Kamath	Corporate Counsel and Company Secretary

Source: Company Website

Top 10 shareholders

Sr. No.	Holder Name	Holding (%)
1	DSP Investment Managers Pvt. Ltd.	5.3
2	HDFC AMC	5.24
3	Kotak Mahindra AMC	2.63
4	ICICI Prudential AMC	2.45
5	Nippon Life India Asset Management	2.21
6	Mirae Asset Global Investments	2.08
7	HDFC Life Insurance Co. Ltd.	2.03
8	Axis AMC	1.77
9	Vanguard Group Inc.	1.70
10	UTI AMC	1.67

Source: Bloomberg

Sharekhan Limited, its analyst or dependant(s) of the analyst might be holding or having a position in the companies mentioned in the article.

Understanding the Sharekhan 3R Matrix

Right Sector	
Positive	Strong industry fundamentals (favorable demand-supply scenario, consistent industry growth), increasing investments, higher entry barrier, and favorable government policies
Neutral	Stagnancy in the industry growth due to macro factors and lower incremental investments by Government/private companies
Negative	Unable to recover from low in the stable economic environment, adverse government policies affecting the business fundamentals and global challenges (currency headwinds and unfavorable policies implemented by global industrial institutions) and any significant increase in commodity prices affecting profitability.
Right Quality	
Positive	Sector leader, Strong management bandwidth, Strong financial track-record, Healthy Balance sheet/cash flows, differentiated product/service portfolio and Good corporate governance.
Neutral	Macro slowdown affecting near term growth profile, Untoward events such as natural calamities resulting in near term uncertainty, Company specific events such as factory shutdown, lack of positive triggers/events in near term, raw material price movement turning unfavourable
Negative	Weakening growth trend led by led by external/internal factors, reshuffling of key management personal, questionable corporate governance, high commodity prices/weak realisation environment resulting in margin pressure and deteriorating balance sheet
Right Valuation	
Positive	Strong earnings growth expectation and improving return ratios but valuations are trading at discount to industry leaders/historical average multiples, Expansion in valuation multiple due to expected outperformance amongst its peers and Industry up-cycle with conducive business environment.
Neutral	Trading at par to historical valuations and having limited scope of expansion in valuation multiples.
Negative	Trading at premium valuations but earnings outlook are weak; Emergence of roadblocks such as corporate governance issue, adverse government policies and bleak global macro environment etc warranting for lower than historical valuation multiple.

Source: Sharekhan Research

DISCLAIMER

This information/document has been prepared by Sharekhan Ltd. (SHAREKHAN) and is intended for use only by the person or entity to which it is addressed to. This Document may contain confidential and/or privileged material and is not for any type of circulation and any review, retransmission, or any other use is strictly prohibited. This information/ document is subject to changes without prior notice.

Recommendation in reports based on technical and derivatives analysis is based on studying charts of a stock's price movement, trading volume, outstanding positions, as opposed to focusing on a company's fundamentals and as such, may not match with a report on a company's fundamentals. However, this would only apply for information/document focused on technical and derivatives research and shall not apply to reports/documents/information focused on fundamental research.

This information/document does not constitute an offer to sell or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Though disseminated to all customers who are due to receive the same, not all customers may receive this report at the same time. SHAREKHAN will not treat recipients as customers by virtue of their receiving this information/report.

The information contained herein is obtained from publicly available data or other sources believed to be reliable and SHAREKHAN has not independently verified the accuracy and completeness of the said data and hence it should not be relied upon as such. While we would endeavour to update the information herein on reasonable basis, SHAREKHAN, its subsidiaries and associated companies, their directors and employees ("SHAREKHAN and affiliates") are under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that may prevent SHAREKHAN and affiliates from doing so. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Recipients of this report should also be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved) and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. We do not undertake to advise you as to any change of our views. Affiliates of Sharekhan may have issued other recommendations/ reports that are inconsistent with and reach different conclusions from the information presented in this recommendations/report.

This information/recommendation/report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SHAREKHAN and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

The analyst certifies that the analyst might have dealt or traded directly or indirectly in securities of the company and that all the views expressed in this document accurately reflect his or her personal views about the subject company or companies and its or their securities and do not necessarily reflect those of SHAREKHAN. The analyst and SHAREKHAN further certifies that either he or his relatives or Sharekhan associates might have direct or indirect financial interest or might have actual or beneficial ownership of 1% or more in the securities of the company at the end of the month immediately preceding the date of publication of the research report. The analyst and SHAREKHAN encourages independence in research report/ material preparation and strives to minimize conflict in preparation of research report. The analyst and SHAREKHAN does not have any material conflict of interest or has not served as officer, director or employee or engaged in market making activity of the company. The analyst and SHAREKHAN has not been a part of the team which has managed or co-managed the public offerings of the company, and no part of the analyst's compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this document. Sharekhan Ltd or its associates or analysts have not received any compensation for investment banking, merchant banking, brokerage services or any compensation or other benefits from the subject company or from third party in the past twelve months in connection with the research report.

Either SHAREKHAN or its affiliates or its directors or employees / representatives / clients or their relatives may have position(s), make market, act as principal or engage in transactions of purchase or sell of securities, from time to time or may be materially interested in any of the securities or related securities referred to in this report and they may have used the information set forth herein before publication. SHAREKHAN may from time to time solicit from, or perform investment banking, or other services for, any company mentioned herein. Without limiting any of the foregoing, in no event shall SHAREKHAN, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind.

Forward-looking statements (if any) are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not a guarantee of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements. Sharekhan/its affiliates undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader/investors are cautioned not to place undue reliance on forward-looking statements and use their independent judgement before taking any investment decision.

Investment in securities market are subject to market risks, read all the related documents carefully before investing. The securities quoted are for illustration only and are not recommendatory. Registration granted by SEBI, and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Client should read the Risk Disclosure Document issued by SEBI & relevant exchanges and the T&C on www.sharekhan.com

Registration and Contact Details: Name of Research Analyst - Sharekhan Limited, Research Analyst Regn No.: INH000006183. (CIN): - U99999MH1995PLC087498.

Registered Office: The Ruby, 18th Floor, 29 Senapati Bapat Marg, Dadar (West), Mumbai – 400 028, Maharashtra, INDIA. Tel: 022-67502000.

Correspondence Office: Gigaplex IT Park, Unit No 1001, 10th floor, Building No.9, TTC Industrial Area, Digha, Airoli-West, Navi Mumbai – 400 708. Tel: 022 61169000 / 61150000, Fax No. 61169699.

Other registrations of Sharekhan Ltd.: SEBI Regn. Nos.: BSE / NSE / MSEI (CASH / F&O / CD) / MCX - Commodity: INZ000171337; DP: NSDL/CDSL-IN-DP-365-2018; PMS: INP000005786; Mutual Fund: ARN 20669. BSE – 748, NSE – 10733, MCX – 56125, MSEI – 1043.

Compliance Officer: Ms. Binkle R. Oza; Tel: 022-62263303; email id: complianceofficer@sharekhan.com

For any complaints/grievance, email us at igc@sharekhan.com or you may even call Customer Service desk on - 022-41523200/022 - 33054600